# Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing

> **NCT03109015** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 7 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03109015
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-27
- **Primary completion:** 2019-10-08
- **Final completion:** 2019-10-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109015, "Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03109015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*